Survivin is an inhibitor of apoptosis protein, which is over-expressed in most tumors. Aberrant expression of survivin and loss of wild-type p53 in many tumors prompted us to investigate a possible link between these two events. Here we show that wild-type p53 represses survivin expression at both mRNA and protein levels. Transient transfection analyses revealed that the expression of wild-type p53, but not mutant p53, was associated with strong repression of the survivin promoter in various cell types. The over-expression of exogenous survivin protein rescues cells from p53-induced apoptosis in a dose-dependent manner, suggesting that loss of survivin mediates, at least, in part the p53-dependent apoptotic pathway. In spite of the presence of two putative p53-binding sites in the survivin promoter, deletion and mutation analyses suggested that neither site is required for transcriptional repression of survivin expression. This was con®rmed by chromatin immunoprecipitation assays. Further analyses suggested that the modi®cation of chromatin within the survivin promoter could be a molecular explanation for silencing of survivin gene transcription by p53.
Introduction
Survivin is an inhibitor of apoptosis protein (IAP) family member (Ambrosini et al., 1997) . As with other IAP proteins, survivin blocks apoptosis induced by a variety of apoptotic triggers (Tamm et al., 1998) . Although the exact biochemical mechanism by which survivin suppresses apoptosis has been debated, survivin has been reported to bind directly to and inhibit caspase-3 and -7, which act as terminal eectors in apoptotic protease cascades (Shin et al., 2001; Tamm et al., 1998) . Antisense targeting of survivin expression resulted in apoptosis (Chen et al., 2000; Olie et al., 2000) . In addition, survivin is regulated in a cell cycledependent manner. Maximal survivin mRNA is expressed in G2/M-synchronized HeLa cells, and the protein is localized to mitotic spindle microtubules (Li et al., 1998) . This suggests that survivin could exert dual control of both the mitotic spindle checkpoint and apoptosis (Li et al., 1998) .
Unlike other members of the bcl-2 and IAP families, survivin has a remarkable expression pro®le. It is completely repressed and undetectable in normal adult tissues but becomes prominently re-expressed in all of the common human cancers tested (Adida et al., 1998; Ambrosini et al., 1997; Grossman et al., 1999; Kawasaki et al., 1998; Lu et al., 1998; Monzo et al., 1999) . Survivin is also abundantly expressed in the human fetus in a developmentally regulated fashion (Adida et al., 1998; Ambrosini et al., 1997; Grossman et al., 1999; Kawasaki et al., 1998; Lu et al., 1998; Monzo et al., 1999) .
The p53 protein is a tumor suppressor gene product that can block progression of cells through the cell cycle and/or induce apoptosis (Sionov and Haupt, 1999; Somasundaram and El-Deiry, 2000; Vogelstein et al., 2000) . Mutation or deletion of p53 is frequently found in a variety of human cancers. The bestcharacterized activity of wild-type p53 is its transactivation function, or its ability to up-regulate the expression of target genes via DNA sequence-speci®c binding. The importance of this activity is underscored by the fact that most p53 mutations found in human cancers prevent DNA binding and compromise this transcriptional activity. p53 triggers cell cycle arrest and apoptosis through transactivation of speci®c target genes, including p21, GADD45, cyclin G1, Bax, fas, IGF-BP3 and PIGs (Asker et al., 1999; Bates and Vousden, 1999) . Transcriptional activation is mediated by p53 binding to a consensus sequence consisting of two copies of a decamer motif 5'-RRRCWWGYYY-3' separated by 0 to 13 bp of random sequence (El-Deiry et al., 1992) . In the motif, R=G or A, W=T or A, Y=C or T, N=any base. In addition, p53 has been shown to repress transcription of a number of genes, including bcl-2, IGF1-R, MAP-4, PS1, etc. which have been implicated in p53-dependent apoptosis (Asker et al., 1999; Budhram-Mahadeo et al., 1999) .
Transcriptional repression mediated by p53 is complex and may be through several distinct mechanisms. Most genes repressed by p53 have no classical p53-binding sites in their promoter. The mechanism is generally ascribed to sequestration of components of the basal transcription machinery by p53 through protein ± protein interactions in the absence of DNA binding (Bargonetti et al., 1997; Borellin and Glazer, 1993; Martin et al., 1993; Seto et al., 1992) . Nevertheless, a few genes have been reported to be repressed by p53 via direct DNA binding (Budhram-Mahadeo et al., 1999; Lee et al., 1999; Ori et al., 1998; Sabbatini et al., 1995) .
Since both over-expression of survivin and loss of wild-type p53 expression are associated with the progressive development of many cancers, we investigated a possible connection between these two events. In this study, we demonstrate that survivin gene expression is repressed by wild-type p53 and survivin plays a role in p53-induced apoptosis.
Results and Discussion
Survivin is repressed at both mRNA and protein level following the expression of p53
To explore the relationship between expression of p53 and human survivin, the human ovarian cancer cell line 2774qw1, which expresses mutant p53, was infected with 10 10 particle/ml of replication-de®cient adenovirus expressing wild-type p53 (rAd-p53) or adenovirus containing empty vector (rAd-control) (Wills et al., 1994) . Analysis of RNAs from 2774qw1 cells using real-time quantitative RT ± PCR revealed time-dependent repression of survivin mRNA by exogenous p53 (Figure 1a ). Survivin mRNA levels remained unchanged until 8 h post infection, and were repressed 3.6-fold by p53 at 16 h post infection as compared to survivin mRNA levels in cells infected with rAdcontrol. A 6.7-fold decrease in survivin mRNA level was observed at 24 h post infection. We then examined the eect of p53 on survivin protein expression ( Figure  1b ). Western blot analysis with an anti-p53 antibody showed two bands, corresponding to endogenous mutant p53 and exogenous wild-type p53 introduced by rAd-p53. The expression of exogenous wild-type p53 protein started at 6 h post infection with rAd-p53 and peaked between 16 and 24 h. It is clear that the expression of survivin protein was inhibited between 16 and 24 h post infection as exogenous wild-type p53 protein levels peaked. To ensure that exogenous wildtype p53 protein can activate the transcription of its target genes in 2774 cells, expression of p21/WAF1, a known p53 target gene, was determined by quantitative RT ± PCR. The mRNA level of endogenous p21/ WAF1 was increased and stayed approximately 100-folds 4 to 24 h post infection of rAd-p53 (data not shown). Taken together, these data indicated that p53-dependent repression of survivin expression occurs at the level of transcription.
Repression of survivin by p53 is not the consequence of cell cycle progression
It is known that the survivin gene expression is regulated in a cell cycle-dependent manner (Li et al., 1998) . To ensure the observed repression of survivin by p53 is not a result of cell cycle eects, we monitored the cell cycle pro®les of 2774qw1 cells infected with rAd-p53 and rAd-control, respectively (Figure 2) . At an early time point (4 h post infection) p53 arrests slightly more cells in the G1 phase of the cell cycle (46%), as compared with cells infected with rAdcontrol (36%). At the same time points endogenous survivin remains unchanged at both RNA and protein levels ( Figure 1 ). When survivin expression was repressed (16 ± 24 h post infection) exogenous p53 arrested slightly more cells (39%) in the G2/M phase compared to the control cells (25 ± 30%). These data suggested that observed p53-dependent repression of Endogenous wild-type p53, but not endogenous mutant p53, represses survivin gene expression
We next tested whether survivin expression could be repressed by physiological induction of endogenous p53 using adriamycin, a DNA damaging agent which is known to induce p53 and apoptosis. Two cancer cell lines were chosen: A549, a human lung cancer cell line harboring wild-type p53, and T47D, a human breast cancer cell line harboring inactive mutant p53 (a Leuto-Phe mutation in codon 194 located in the DNAbinding domain). Between 0 to 8 h after adriamycin treatment, there were similar patterns of survivin expression in T47D and A549 cells (Figure 3 ). Eight hours after addition of adriamycin to A549 cell cultures, survivin mRNA was substantially reduced in A549 cells whereas the level of survivin mRNA remained unchanged in T47D cells. Thus, the results suggested that the regulation of survivin gene expression by wild-type endogenous p53 induced by a DNA damaging agent is identical to that observed upon over-expression of exogenous wild-type p53.
Overexpression of survivin inhibits p53-dependent apoptosis p53 transcriptionally regulates a number of genes that control apoptosis (Sionov and Haupt, 1999) . Survivin has been described as an apoptosis inhibitor (Li et al., 1998; Lu et al., 1998; Shin et al., 2001 ) and repression of survivin by p53 is likely to contribute to p53-induced apoptosis. We monitored the apoptotic response of A549 cells following adriamycin treatment by measuring fragmentation of genomic DNA. A549 cells, which express a functional p53 that represses survivin expression, undergo apoptosis in response to the DNA damage by adriamycin (Figure 4a ). In contrast, adriamycin was not able to induce apoptosis in T47D cells containing mutant p53. Repression of human survivin gene expression correlated with apoptosis in response to induction of endogenous wild-type p53, suggesting a role for repression of survivin expression in p53-dependent apoptosis. This hypothesis is supported by the ®nding that an antisense oligonucleotide that eciently repressed survivin mRNA directly induced apoptosis in A549 cells (Olie et al., 2000) . To test the eect of survivin expression on p53-induced apoptosis, we transfected a survivin expression plasmid into A549 cells. The expression of survivin protein was con®rmed by Western analysis (data not shown). Over-expression of exogenous survivin reduced the level of apoptotic response to adriamyin in a dose-dependent manner ( Figure 4b ). This suggests that survivin down-regulation may participate in p53-mediated apoptotic pathway. This is supported by the observations in a recent study that expression of survivin could substitute for the loss of p53 to suppress UVB-induced apoptosis in vivo (Grossman et al., 2001 ).
Wild-type but not mutant p53 represses survivin promoter activity
To determine whether the decrease in the steady-state survivin mRNA level following p53 expression is due to repression of survivin promoter activity, a luciferase reporter construct was made. The 2.3 kb survivin promoter fragment (nucleotides, 71906 to +366) was ampli®ed by polymerase chain reaction and cloned into a luciferase reporter plasmid, designated SP13, as Figure 2 The repression of survivin expression by p53 is independent of cell cycle progression. FACS analysis of 2774qw1 cells at indicated time points post infection with rAdp53 or rAd-control Figure 3 Endogenous wild-type p53, but not endogenous mutant p53, represses human survivin gene expression. mRNA level of survivin gene is repressed in A549 cells following treatment with 500 nM adriamycin at the indicated times. mRNA levels were determined using Taqman quantitative RT ± PCR assay as described under Materials and methods. Similar determinations were made with T47D cells treated with 500 nM adriamycin at the indicated times. Data points are from a representative experiment of two independent experiments described under Materials and methods ( Figure 5a ). The initial approach to study p53 regulation of this promoter was to transfect the SP13 plasmid into the Saos-2 cell line, which does not contain or express p53, together with wild-type p53 or mutant p53 expression plasmids (or expression vector alone). The empty luciferase reporter vector (Basic) was used as a control for p53 induced non-speci®c change in transcription. Minimal luciferase activity was detected in Saos-2 cells transfected with the empty vector. In the absence of p53, the 2.3 kb survivin promoter in SP13 produces high basal luciferase activity, giving rise to a 4.4-fold higher luciferase activity than that of the empty vector (data not shown), in agreement with published results . As expected, wild-type p53 is able to reduce luciferase activity about 5.5-fold in Saos-2 cells (Figure 5b ). In contrast, mutant p53 had very little eect on survivin promoter activity under identical assay conditions. These results demonstrate that the expression of wild-type p53 protein, but not mutant p53, repressed transcriptional activity of the survivin gene promoter. We next examined whether p53-repressed transcription of the survivin promoter is cell type dependent. The human ovarian tumor cell lines, 2774 cells and PA-1, were used. 2774 cells contain an Arg273His p53 mutation, and PA-1 cells have a silent mutation in the p53 gene and express functional p53 (Santoso et al., 1995; Yaginuma and Westphal, 1992) . Again, transient transfection analysis of p53 expression with the SP13 reporter gene showed that wild-type p53 repressed survivin promoter activity in 2774 cells (2.7-fold) and in PA-1 cells (4.7-fold), while mutant p53 protein failed to repress luciferase activity (Figure 5b ). Similar results were observed when SP13 was transfected into A549 cells treated with 500 nM adriamycin for 24 h. The endogenous wild-type p53 represses survivin promoter activity approximately 3.9-fold compared to cells treated with DMSO (data not shown). Taken together, these data indicate that wild-type p53 can be a repressor of the survivin promoter in a variety of human cancer cell lines whereas mutant p53 lacks this repressor activity.
Repression of the survivin promoter activity by p53 requires a region proximal to the transcription start site
The search of the p53 Target Database (Wang et al., 2001) revealed that the human survivin gene has two copies of a p53-binding sequence in its promoter region (Figure 5a ). These two putative p53-binding sequences are located at nucleotide position 77 (p53S1) and 71294 (p53S2) relative to the proximal transcriptional start site (+1) determined by primer extension and S1 nuclease mapping methods . Both p53-binding sequences have a 3 bp insert between the two decamers and three mismatches in the decamers. To explore a possible role of these sequences in the repression of survivin gene expression by p53, a series of 5' deletions of the survivin promoter sequence (nucleotides 71895 to +366) were prepared using PCR as described under Materials and methods (Figure 5a ). The construct SP13 was used as a template for PCR reaction. To remove the upstream p53-binding sequence (p53S2), the 5' sequence in SP13 was deleted from nucleotides 71895 to 71261, designated as Del-1. The basal level of Del-1 was similar to that seen with the SP13 construct, and expression of wild-type p53 in 2774 cells resulted in repression of luciferase activity (Figure 5c ), suggesting that the removal of the upstream p53 binding sequence has no eect on survivin expression. The deletion to nucleotide 771 resulted in a construct, Del-2, which also retained p53 repression of luciferase activity (Figure 5a and c) . Similar results were observed with (Figure 5d ). To remove the proximal p53-binding site (p53S1), the reporter gene was further deleted to nucleotides seven base pairs upstream of transcription start site (Del-3) (Figure 5a ). The transfection results indicated that the deletion in Del-3 abolished the basal luciferase activity (Figure 5c ). Therefore, the deletion analysis indicated that the 5' boundary of the survivin promoter essential for p53 repression could be de®ned at least from nucleotides 771.
To further determine the role of the proximal p53-binding sequence in p53-dependent repression of the survivin gene, the sequence of the p53S1 in the construct Del-2 was mutated by base substitutions. Transient transfection experiments indicated that these mutants remained sensitive to p53-dependent repression of luciferase activity, suggesting that the putative proximal p53 binding sequence in the survivin promoter is not functional. Furthermore, the p53S2 sequence in the construct SP13 was mutated to determine the potential role of the p53S2 although deletion analyses suggested that the p53S2 is not essential for p53-dependent repression of survivin expression. The results of transient transfection experiments with mutants of the p53S2 agree the conclusion derived from deletion analyses. Therefore, neither site is necessary for p53-dependent repression of survivin expression and p53 may repress survivin expression via mechanisms other than direct DNA binding.
Repression of survivin gene expression results from suppression of histone acetylation of the promoter but not direct DNA binding Histone acetylation is known to contribute to gene activation while histone deacetylation is thought to be an active mechanism that leads to gene repression (Brownell and Allis, 1996; Hirose, 1998; Kiermaier and Eilers, 1997; Pazin and Kadonga, 1997) . Chromatin immunoprecipitation (ChIP) assays have been successfully used to detect in vivo protein-DNA interactions (Eberhardy et al., 2000; Frank et al., 2001; Takahashi et al., 2000) . We next examined the in¯uence of adriamycin on the status of histone acetylation using The indicated survivin promoter constructs were transiently transfected into 2774 cells in the presence of wildtype p53 or empty expression vector alone. The empty luciferase reporter vector (BASIC) was used as a control for p53 induced non-speci®c change in transcription. (d) The Del-2 luciferase reporter construct was transfected into A549 cells that express wild-type p53 and treated with 500 nM adriamycin (Adr.) or DMSO for 24 h, respectively. The level of luciferase activity was determined in cell lysates 48 h after transfection as described under Materials and methods. Values are normalized relative to the value obtained with expression vector or DMSO alone (set at 100%). The error bars indicate standard deviations from triplicate measurements and the data are representative of three independent transfections ChIP assay. Human lung tumor A549 cells were treated with 500 nM adriamycin or vehicle (DMSO) for 24 h, and processed with formaldehyde to crosslink protein to DNA. Samples were sonicated prior to immunoprecipitation with speci®c antibody against acetylated histone H3. After immunoprecipitation, proteins were digested and the enrichment of speci®c DNA fragments was analysed by real-time quantitative PCR using primers speci®c to the region proximal to the transcription start site of the survivin gene ( Figure  6a ). Taqman analysis of acetylated histone H3 speci®c antibody immunoprecipitates demonstrated an enrichment of DNA fragments which contain the region proximal to the start site of the survivin promoter in the control cells treated with DMSO (Figure 6b ). The highly acetylated chromatin of the survivin promoter will allow site speci®c transcription factors and the RNA polymerase II basal transcriptional machinery access to the start site of transcription. As expected, a pronounced decrease in histone H3 acetylation at the same region was observed in the adriamycin-treated cells. Decreased histone acetylation would result in alteration of chromatin structure and suppress access of transcription factors to nucleosomal DNA, leading to transcriptional repression of survivin.
It has been demonstrated that histone deacetylases (HDAC) in complex with p53 results in active repression of the p53 target genes, MAP4 and stathmin (Murphy et al., 1999) . To investigate the eect of HDAC on acetylation state of the survivin promoter, a speci®c HDAC inhibitor, trichostatin A (TSA), was used. Cells were treated with adriamycin for 24 h and TSA for 1 h before harvesting cells for isolation of histones. Taqman analysis of the immunoprecipitates revealed that TSA treatment causes an increase in the amount of acetylated histone H3 associated with the survivin promoter in the region that is responsible for the repression (Figure 6b ). This suggests that the acetylation state of histone H3 is regulated by HDAC.
We validated the ChIP assays by examining the interaction between p53 and a functional p53 response element in the promoter of a known p53 target gene, PCNA (Morris et al., 1996) . A p53 speci®c antibody was used in the ChIP assays. We observed that overexpression of p53 causes an increase in the amount of both p53 and acetylated histone H3 on the PCNA promoter (data not shown). It suggests that p53 acts as a transactivator on the PCNA promoter and local chromatin is highly acetylated so that the promoter becomes accessible to the transcription factors.
In addition, we would like to determine, using the ChIP technique, whether p53 interacts with the survivin promoter in vivo using the primers speci®c to the p53S1 and the p53S2, respectively (Figure 6a , data not shown). The ChIP assays were ®rst carried out in A549 cells, where endogenous wild-type p53 could be induced by the treatment of adriamycin. The results indicated that p53 does not interact in vivo with two putative p53 binding sequences in the survivin promoter in both adriamycin-treated and untreated A549 cells (data not shown). Furthermore, the in vivo binding of p53 on the survivin promoter was examined in 2774qw1 cells 16 h post infection of rAd-p53 or rAd-control. Over-expression of exogenous p53 in 2774qw1 cells also does not result in direct interaction of p53 with the p53S1 and the p53S2 (data not shown). In contrast, a recent paper (Homan et al., 2002) reported that p53 directly interacts with the survivin promoter to repress survivin expression in Murine Val5 cells, which over-express the temperature-sensitive Valine 135 allele of p53. Our promoter mutational analyses and ChIP analyses do not support this conclusion. Taken together, our data indicate that the activation or repression or survivin gene expression depends on the acetylation state of the local promoter and not on direct DNA binding. Because TSA treatment altered the acetylation state of the local chromatin, we hypothesized that HDAC may modify the local chromatin to repress survivin transcription, providing a molecular explanation for p53-dependent repression of survivin expression. Survivin promoter activity was repressed in A549 cells in response to 24 h treatment with adriamycin. A549 cells transfected with Del-2 construct were treated with adriamycin in the presence of TSA in ethanol or vehicle for 18, or 24 h before harvesting cells. TSA treatment eectively abrogates the repression of survivin promoter activity upon induction of endogenous p53 in A549 cells (Figure 7 ). This suggests that the deacetylase activity is required for p53-dependent repression of survivin expression.
To determine whether the observed repression of survivin by p53 was associated with recruitment of HDAC complexes in vivo, we ®rst examined the presence of endogenous HDAC-1 and HDAC-2 in 2774qw1 cells. By Western analysis, HDAC-2, instead of HDAC-1, was detected in 2774qw1 cells (Figure 8a ). We next analysed the association between p53 and HDAC-2 by co-immunoprecipitation and Western blotting lysates of 2774qw1 cells infected with rAdp53. We found that HDAC-2 is in a complex with p53 in 2774q21 cells (Figure 8b) . A similar observation was made in A549 cells (data not shown). Therefore, we hypothesize that wild-type p53 may act as a transcriptional repressor by recruiting the HDAC complex in vivo and that HDAC-2 may involve in p53-dependent repression of survivin expression.
Conclusion
Our studies have demonstrated that the accumulation of wild-type p53 leads to repression of survivin expression, which is independent of cell cycle progression. The temporal pro®le of survivin gene expression correlated with the kinetics of the apoptotic process in response to p53 expression. Over-expression of survivin in apoptotic cells induced by p53 causes resistance to apoptosis, suggesting a role for survivin in the p53-dependent apoptotic pathway. Dissection of regulatory mechanisms by various analyses suggested that transcriptional repression of survivin expression does not require direct sequence-speci®c DNA binding of p53 to the promoter though there are two putative p53 binding sites in the survivin promoter. Chromatin deacetylation in the survivin promoter may contribute to p53-dependent repression of survivin gene expression. This conclusion agrees well with a general mechanism of p53-mediated repression ascribed to sequestration of components of the basal transcription machinery by p53 through protein ± protein interactions in the absence of direct DNA binding (Bargonetti et al., 1997; Borellin and Glazer, 1993; Martin et al., 1993; Seto et al., 1992) . Our studies have made a link between aberrant expression of survivin and loss of wild-type p53 in the progression of many tumors.
Materials and methods

Cell lines and antibodies
The human ovarian cancer cell line 2774, the human breast cancer cell line T47D, the human lung cancer cell line A549, and the human ovarian cancer cell line PA-1 were obtained from American Type Cell Collection. The cell line, 2774qw1, was a single clone derived from human ovarian cancer cell line 2774. Culture conditions of all cell lines followed the Figure 7 The Del-2 luciferase reporter construct was transfected into A549 cells that express wild-type p53 and treated with 500 nM adriamycin (Adr.) for 24 h and with vehicle or TSA for 18 or 24 h before harvesting cells, respectively. The level of luciferase activity was determined in cell lysates 48 h after transfection as described under Materials and methods. Values are normalized relative to the value obtained with adriamycintreated samples (set at 100%). The error bars indicate standard deviations from triplicate measurements and the data are representative of three independent transfections instructions from ATCC. Antibodies that recognize p53 (Ab-5, Ab-6) and b-actin (CP01) were obtained from Oncogene Research Products. Antibody SURV-11A was purchased from Autogen Bioclear. Antibodies that recognized HDAC-1 (sc-6298) and HDAC-2 (sc-9959) were purchased from Santa Cruz Biotechnology, Inc. Anti-acetylated histone H3 (06-599) was obtained from Upstate Biotechnology.
Treatment of cells with adriamycin or recombinant adenoviruses expressing p53
The infection of 2774qw1 cells with 10 10 particle/ml of rAdp53 to introduce exogenous p53 was performed as described previously (Wang et al., 2001) . To induce endogenous p53, A549 and T47D cells were treated with 500 nM adriamycin or vehicle alone as described previously (Wang et al., 2001) . The virus-infected or adriamycin-treated cells were harvested at indicated time points and cell pellets were prepared for apoptosis assays, RNA isolation, chromatin immunoprecipitation, transient transfection or Western blot analyses.
RNA isolation and quantitative RT ± PCR
Total RNA was isolated using a CsCl puri®cation method as described (Chirgwin et al., 1979) . The relative mRNA levels of human survivin, p21/WAF1, and exogenous p53 were measured with the TaqMan 5' nuclease quantitative RT ± PCR assay as described previously (Wen et al., 2000) . Taqman EZ RT ± PCR kit (PE Applied Biosystems) was used to perform the quantitative RT ± PCR on 7700 Sequence Detector (PE Applied Biosystems). The fold change of survivin mRNA level in the samples infected with rAd-p53 at each time point was calculated relative to that in the samples infected with rAd-control at the corresponding time point. All data points were normalized to an endogenous control, human beta-glucronidase mRNA, whose expression remains relatively consistent across the test samples. All measurements were done in at least two independent experiments, each of which was done in triplicate.
Immunoprecipitation and Western blot analysis
One hundred mg of total protein extract was immunoprecipitated overnight with 1mg of antibody speci®c for p53 (Ab-6) as described (Frank et al., 2001) . For Western blot analysis, 60 mg of total cellular protein, which was determined using BCA* Protein Assay Reagent (Pierce), was electrophoresed on 4 ± 20% acrylamide gels, transferred onto nitrocellulose, and probed with antibodies of anti-survivin (SURV-11A), anti-p53 (Ab-5), anti-HDAC-1 (sc-6298), anti-HDAC-2 (sc-9959) or anti-b-actin (CP01). The antibodies were diluted according to the manufacturer's instructions. Secondary HRP-linked antibodies to mouse and rabbit were obtained from Jackson Immunoresearch. Proteins were detected by chemiluminescence (ECL, Amersham).
Cell cycle analysis
2610
6 cells were grown in 10-cm tissue culture dishes and infected with rAd-p53, or rAd-control as described above. The cells were trypsinized, washed with PBS, ®xed with 70% methanol for 30 min at 48C, washed with PBS and stained with propidium iodide solution (0.05 mg/ml propidium iodide, 0.1% Triton X-100, 0.1 mM EDTA, 0.05 mg/ml RNase A). Approximately 12 000 stained cells were analysed by¯ow cytometry in a Becton Dickinson FACS Vantage¯ow cytometer. Data was analysed using ModFit LT version 3 (Verity Software House Inc.).
Apoptosis assays
Apoptosis analysis was performed using Cell Death Detection ELISA PLUS (Boehringer-Mannheim) to measure DNA fragmentation, following the manufacturer's instruction. Brie¯y, cells were seeded at a density of 1610 4 cells per well in a 96-well format. Cells were lysed in 200 ml lysis buer and incubated at room temperature for 30 min. Twenty ml of supernatant was transferred into an ELISA microtiter plate for analysis. Absorbance was measured at 405 nm and 490 nm on a Thermo Max Microplate Reader (Molecular Devices).
Luciferase reporter gene constructs
In order to identify a genomic clone that contained the human survivin promoter sequence, human BAC libraries (Genome Systems, Inc.) were screened by PCR. The sequences of the oligonucleotide primers are listed as follows: 1281surF, 5' GAA AAT CTG GGT GAA GG 3', Tm=53.88C and 1609surR, 5' CTC TAT CGC CCA GGC TG 3', Tm=61.18C; 2914surF, 5' CGG AGC GGG TGA GAC TGC 3', Tm=68.98C and 3128surR, 5' GAC GTG GCA GCC CGG AAC 3', Tm=71.28C. The amplicon sizes for each pair of primers were 328 bp and 214 bp, respectively. The identi®ed human BAC clone 24471 containing survivin genomic sequences was streaked on LB agar plates, and a single colony was used to inoculate a large scale BAC plasmid preparation. BAC DNA was isolated using the KB-100 (magnum) puri®cation kit (Genome Systems, Inc.). A fragment containing the promoter region of survivin from 71906 to +366 was PCR-generated using the primer sequences for SP13 listed in Table 1 . The BAC clone 22471 was used as a template, and 28 cycles of ampli®cation were carried out with p.f.u. Turbo polymerase (Stratagene). Cycling conditions were as follows: denaturation at 958C for 1 min, annealing at 708C for 1 min, and extension at 758C for 5 min, with a ®nal 7 min extenstion at 758C. Serial deletions of the survivin promoter, Del-1, Del-2 and Del-3, were also PCR-generated using the primer sequences listed in Table 1 . SP13 was used as a template, and Taq (Roche Biochemical) was used as the enzyme in all reactions. Cycling conditions were as follows: (28 cycles) denaturation at 958C for 1 min, annealing at 558C for 1 min, and extension at 728C for 2 min, with a ®nal 7 min extension at 728C. All PCR products were gel-puri®ed, digested with SacI and HindIII, and ligated into the pGL3 Luciferase Reporter Vector (Promega).
All PCR reactions were carried out in a Perkin-Elmer 9700 GeneAmp PCR System, and all recombinant and mutated constructs were con®rmed by sequence analysis on a PerkinElmer ABI Prism 377 or 310 DNA sequencer.
Transient transfections and luciferase assays
2774 or A549 cells were plated at a density of 2610 5 cells per well in 6-well dishes. Transfections with Lipofectamine (Gibco-BRL) were performed as per the manufacturer's instructions. Brie¯y, the cells were incubated for 5 h at 378C in 5% CO 2 with 2 to 3 mg DNA (expression plasmids for murine wt p53, inactive R175H p53 mutant and/or empty cassette plasmid) and 6 ml Lipofectamine in Opti-MEM. Cells were then washed and fed with complete growth medium and incubated for an additional 48 h. Lysates were obtained using the Luciferase Assay System kit (Promega), following the manufacturer's instructions. Luciferase activity was measured with a Dynex MLX Microtiter Plate Luminometer.
Chromatin immunoprecipitation assays
Approximately 1610 7 A549 cells were harvested 24 h after treatment with 500 nM adriamycin or vehicle in the absence or presence of 500 ng/ml of TSA. The ChIP assays were performed as described previously (Wang et al., 2001) . Brie¯y, the chromatin was incubated overnight with each antibody: p53 (Ab-6), acetylated histone H3 (06 ± 599), or no antibody added as a negative control. The enrichment of speci®c DNA fragments was analysed by real-time quantitative PCR on Taqman (PE 7700) with site-speci®c primers and probes. The sequences of primers and probe, obtained from PE, Applied BioSystems, are listed as follows: survivin, surF: 5' TGGGTGCCCCGACGT 3', surR: 5' GAAGGGC-CAGTTCTTGAATGTAGA 3', and Sprobe: 5' CCTGCCTGGCAGCCCTTTCTCA 3'. Sprobe was labeled with a reporter¯uorescent dye ] at the 5' end and a quencher¯uorescent dye TAMRA (6-carboxyl-tetramethyl-rhodamine) at the 3' end were added to the PCR reaction.
Abbreviations IAP, inhibitor of apoptosis protein; rAd-p53, recombinant adenovirus encoding wild-type p53; rAd-control, recombinant adenovirus containing empty vector; HDAC, histone deacetylase complex; ChIP, chromatin immunoprecipitation; PCNA, proliferating cell nuclear antigen; TSA, trichostatin A
